TO: The Australian Colleges and Associations of Medicine, Health, and Science, and All Australian Federal, State, and Territory Senators and Members of Parliament
It is with great pleasure that I introduce you and your respective organisations to the Australian Medical Professionals Society. This email deals with several issues which are of concern to our membership and, we hope, yours. At the top of the list is the issue of medical free speech and its ramifications for true dialogue, debate, and informative patient interaction in Australia. Also, this email and the report of Dr Phillip Altman, makes available to you and your members a cutting edge update on the COVID-19 vaccinations and a comprehensive analysis of associated Adverse Events, together with implications for Australian practice. Finally, we draw your attention to our Health Reform Declaration, a statement which is gaining support as it highlights critical issues and potential solutions, within the complex environment of Australian Health Law.
Australian Health Professionals and Scientists have been actively discussing and contemplating the profound health measures undertaken within Australia over the last 2&1/2 years. However, we believe the current range of medical, medicolegal and medicopolitical issues brought about by the pandemic requires a greater breadth of discussion – not less – within and between our respective organisations and memberships.
One of the chief concerns of our membership is that of medical free speech. Contingent to a joint statement received from AHPRA and the National Boards on 9 March 20211, Australian Health Professionals numbering over 825,000 were essentially forbidden from publicly questioning the science underlying the emerging COVID-19 injectables, let alone questioning any government messaging urging Australians to be vaccinated because these products were deemed ‘safe and effective’. The effect of this unilateral action was to undermine professional independence and, in so doing, strip away years of training, academic achievements, qualifications, awards and expertise. However well intentioned, this gagging by bureaucratic decree inserted AHPRA and the National Boards between the Clinician and their Patient, in addition to counteracting normal robust interprofessional dialogue, as more data emerged.
Indeed, now 17 months later and after numerous forms of pressure to take up the COVID-19 injectables in various age categories, a tremendous amount of data is available to more fully and accurately inform clinicians about these products. This literature includes over one thousand2 peer reviewed studies reporting of the harms being seen around the world, up to December 2021. In addition, it has become clear that the risk of serious illness and death attributable to COVID-19 disease is heavily weighted to the elderly and those with known co-morbidities, while in contrast, younger Australians are relatively resistant. Also, since the advent of the Delta and Omicron variants, it is highly questionable whether the vaccines are preventing transmission or illness.
In any event, the implied and intended outcome of the gagging was to see Doctors and Health Professionals effectively mandated to support the government campaign to have the Australian population injected with drugs for which there was no adequate short-, medium-, or long-term safety or efficacy data. Indeed, the rush to market and Provisional Approval occurred despite the absence of the usual pre-clinical studies, including testing for Carcinogenicity and Genotoxicity. In this regard, it should be of serious interest that a peer-reviewed investigation3 has demonstrated that mRNA-derived Spike proteins enter the cell nucleus and interfere with DNA. However, many critical facts like these became forbidden subjects for Health Professionals and Doctors to raise with their patients, let alone in public forums. Thus, we contend that the joint statement of 9 March 2021 has compromised proper and informed consent in Australia.
Especially given the lack of available pre-clinical research for each of these products, or clinical studies powered to detect early safety signals at the time of Provisional Approval, the need for ongoing critical appraisal of pharmacovigilance data remains paramount, to instruct responsible day to day practice. To date, none of the makers of the COVID-19 injectables have been able to stringently show their products to be Safe or properly Effective. To date, Adverse Events flowing from these products are at historically unprecedented levels globally and continue to rise. And again, to date, no other drugs in human history have reported more deaths, illnesses, injuries, and disabilities, which number as follows (to 28 June 2022):